^
HER-2 positive
Salivary Gland Cancer
trastuzumab
Sensitive: A1 - Approval
Chugai Press Release - 1 week
No biomarker
Salivary Gland Cancer
cisplatin + doxorubicin hydrochloride + cyclophosphamide oral
Sensitive: A2 - Guideline
No biomarker
Salivary Gland Cancer
cisplatin + vinorelbine tartrate
Sensitive: A2 - Guideline
NTRK2 fusion
Salivary Gland Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Salivary Gland Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Salivary Gland Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Salivary Gland Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Salivary Gland Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Salivary Gland Cancer
entrectinib
Sensitive: A2 - Guideline
AR positive
Salivary Gland Cancer
leuprolide acetate
Sensitive: A2 - Guideline
AR positive
Salivary Gland Cancer
bicalutamide
Sensitive: A2 - Guideline
PD-L1 expression
Salivary Gland Cancer
pembrolizumab
Sensitive: C1 - Off-label
HER-2 overexpression
Salivary Gland Cancer
trastuzumab
Sensitive: C1 - Off-label
RET fusion
Salivary Gland Cancer
selpercatinib
Sensitive: C1 - Off-label
RET fusion
Salivary Gland Cancer
pralsetinib
Sensitive: C1 - Off-label
HER-2 overexpression
Salivary Gland Cancer
trastuzumab
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
Salivary Gland Cancer
ado-trastuzumab emtansine
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
Salivary Gland Cancer
trastuzumab
Sensitive: C2 – Inclusion Criteria
AR positive
Salivary Gland Cancer
leuprolide acetate + bicalutamide
Sensitive: C3 – Early Trials
PLIN2 expression
Salivary Gland Cancer
leuprolide acetate + bicalutamide
Sensitive: C3 – Early Trials
AKT1 E17K
Salivary Gland Cancer
AZD5363
Sensitive: C3 – Early Trials
HER-2 expression
Salivary Gland Cancer
ARX788
Sensitive: C3 – Early Trials
HRAS mutation
Salivary Gland Cancer
tipifarnib
Sensitive: C3 – Early Trials
HER-2 amplification
Salivary Gland Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: C3 – Early Trials
HER-2 expression
Salivary Gland Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: C3 – Early Trials
PTEN expression
Salivary Gland Cancer
bicalutamide
Sensitive: C3 – Early Trials
PTEN expression
Salivary Gland Cancer
trastuzumab
Sensitive: C3 – Early Trials
PTCH1 mutation
Salivary Gland Cancer
vismodegib
Sensitive: C3 – Early Trials
HER-2 amplification
Salivary Gland Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
HER-2 amplification
Salivary Gland Cancer
pyrotinib
Sensitive: C3 – Early Trials
HER-2 overexpression
Salivary Gland Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
MET N375S
Salivary Gland Cancer
crizotinib + pazopanib
Sensitive: C3 – Early Trials
ETV6-NTRK3 fusion
Salivary Gland Cancer
larotrectinib
Sensitive: C3 – Early Trials
AR positive
Salivary Gland Cancer
abiraterone acetate
Sensitive: C3 – Early Trials
AR positive + HER-2 amplification
Salivary Gland Cancer
leuprolide acetate + bicalutamide
Sensitive: C4 – Case Studies
BAG4-FGFR1 B2F6
Salivary Gland Cancer
ABSK-091
Sensitive: C4 – Case Studies
ETV6-NTRK3 fusion
Salivary Gland Cancer
entrectinib
Resistant: C4 – Case Studies
PIK3CA H1047R
Salivary Gland Cancer
vandetanib
Sensitive: C4 – Case Studies
HER-2 amplification + HER-2 mutation
Salivary Gland Cancer
trastuzumab
Sensitive: C4 – Case Studies
HER-2 positive
Salivary Gland Cancer
ACE1702
Sensitive: C4 – Case Studies